Provided by Tiger Trade Technology Pte. Ltd.

Fulcrum Therapeutics

6.73
-0.2100-3.03%
Post-market: 6.730.00000.00%17:20 EDT
Volume:390.89K
Turnover:2.64M
Market Cap:448.22M
PE:-5.69
High:7.00
Open:6.93
Low:6.68
Close:6.94
52wk High:15.74
52wk Low:2.32
Shares:66.60M
Float Shares:39.39M
Volume Ratio:0.26
T/O Rate:0.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1819
EPS(LYR):-1.1819
ROE:-25.30%
ROA:-16.90%
PB:1.28
PE(LYR):-5.69

Loading ...

Fulcrum Therapeutics Announces Positive 12-Week Results From the 20 Mg Dose Cohort of the Phase 1B Pioneer Trial of Pociredir in Sickle Cell Disease

THOMSON REUTERS
·
Feb 24

Fulcrum Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview

Reuters
·
Feb 20

Fulcrum Acquires Wildnote to Expand Platform Capabilities for Environmental Compliance

THOMSON REUTERS
·
Feb 17

Fulcrum Therapeutics Announces 12-Week Results from Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Reuters
·
Feb 17

Fulcrum’s Pociredir Trial Completion Adds a New Catalyst to the Sickle Cell Investment Story

TIPRANKS
·
Feb 13

Fulcrum Therapeutics Grants 70,000 Stock Options to New Employee

Reuters
·
Feb 07

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 07

Director Robert J. Gould Reports Sale of Fulcrum Therapeutics Inc. Common Shares

Reuters
·
Feb 05

Truist Financial Sticks to Their Buy Rating for Fulcrum Therapeutics (FULC)

TIPRANKS
·
Feb 02

Fulcrum and Kpmg Announce Collaboration to Transform Utility Field Operations and Strengthen Operational Resiliency

THOMSON REUTERS
·
Jan 27

De-Risked Efficacy and Clean Safety for Pociredir in Sickle Cell Disease Position FULC for Re-Rating Ahead of 1Q26 Data

TIPRANKS
·
Jan 26

Fulcrum Therapeutics (FULC) Receives a Sell from Bank of America Securities

TIPRANKS
·
Jan 16

Fulcrum Therapeutics Showcases Pociredir's Promise as Best-in-Class Oral Therapy for Sickle Cell Disease

Reuters
·
Jan 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fulcrum Therapeutics (FULC), Teladoc (TDOC) and MDxHealth (MDXH)

TIPRANKS
·
Jan 13

Fulcrum Therapeutics updates strategy on lead sickle cell therapy

TIPRANKS
·
Jan 12

Fulcrum Therapeutics Initiated at Overweight by JP Morgan

Dow Jones
·
Jan 12

JPMorgan Initiates Coverage on Fulcrum Therapeutics With Overweight Rating, $20 Price Target

MT Newswires Live
·
Jan 12

Fulcrum Therapeutics Inc : JP Morgan Initiates Coverage With Overweight Rating; Price Target $20

THOMSON REUTERS
·
Jan 12

Fulcrum Therapeutics Grants Stock Options to New Employees

Reuters
·
Jan 10

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 10